🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07374952
Recruiting Phase 4

Minimal Effective Volume 90% for Double-injection Costoclavicular Block

NCT07374952 · tracked via the Priya Life Science Canada tracker
Phase
Phase 4
Started
2026-06-16
Last updated
2026-07-07

Condition(s) studied

Brachial Plexus BlocksLidocaineNerve BlockDose Finding StudyCostoclavicular Block

Investigational drug(s) / intervention(s)

Ultrasound-guided double-injection costoclavicular nerve block with same previous volumeUltrasound-guided double-injection costoclavicular nerve block with lower volume

Ultrasound-guided double-injection costoclavicular nerve block with same previous volume: ultrasound-guided double-injection costoclavicular nerve block with the same volume used in the previous successful block

Ultrasound-guided double-injection costoclavicular nerve block with lower volume: Ultrasound-guided double-injection costoclavicular nerve block with lower volume than the previous successful block

Study summary

In 2020, a trial demonstrated that a 2-injection technique constitutes the optimal method for the costoclavicular block.

This study aims to determine the minimum amount of medication required to achieve a successful double-injection costoclavicular nerve.

Block dose assignment will be done using an up-and-down sequential method, called the Biased Coin Design (BCD).

The double-injection technique for US-guided costoclavicular block consists in depositing two thirds of the LA volume in the deep compartment (to anesthetize the posterior and medial cords), and one third of the injectate in the superficial compartment (to anesthetize the lateral cord).

The ED90 will be calculated using isotonic regression with a 95% confidence interval derived by bootstrapping.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 70 years * American Society of Anesthesiologists classification 1-3 * Body mass index between 20 and 30 Exclusion Criteria: * Adults who are unable to give their own consent * Pre-existing neuropathy (assessed by history and physical examination) * Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets≤ 100, International Normalized Ratio≥ 1.4 or partial prothrombin time ≥ 50) * Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine≥ 100) * Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases≥ 100) * Allergy to LA * Pregnancy * Prior surgery in the infraclavicular region * Chronic pain syndromes requiring opioid intake at home

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Montreal General Hospital Montreal Quebec Recruiting

More McGill University Health Centre/Research Institute of the McGill University Health Centre trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07374952 on ClinicalTrials.gov ↗ ← All trials in Canada